Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$253.62 ▲ +3.97
(+1.59%)
MKT CAP: $37.49B • VOL: 1.30M
52W L $149 52W H $259
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$213
MEDIAN
$284
MEAN
$289
HIGH
$345
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE BIIB TAPE
BIIB // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $306.88 | $291.66 | 2025-02-14 | $230.79 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $319.56 | $299.27 | 2025-02-06 | $238.40 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $289.13 | $278.98 | 2025-01-29 | $243.48 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $258.69 | — | 2025-01-17 | $248.55 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $223.19 | $240.94 | 2025-01-09 | $225.72 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $301.81 | $263.76 | 2024-12-18 | $220.65 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $246.01 | $256.16 | 2024-12-04 | $235.87 | -4.3% | 48% | C |